Adial Pharmaceuticals raises $2.86M via warrant inducement; issues new Series F warrants for up to 13.8M shares

ADIAL PHARMACEUTICALS, INC.

Holder exercised 9,215,675 existing Series C-1 and E warrants at $0.31/share, generating gross proceeds of $2.86M.
In consideration, company issued new unregistered Series F warrants to purchase up to 13,823,512 shares at $0.31.
New warrants exercisable only after stockholder approval, term 24 months from approval date; company must seek approval within 120 days of closing.
Company agreed to 60-day standstill on equity issuances (except ATM after 31 days) and 6-month no variable rate transactions.
A.G.P./Alliance Global Partners acted as financial advisor with an 8% fee on gross proceeds.

item 1.01 item 3.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

ADIAL PHARMACEUTICALS, INC. issued up to 13,823,512 shares of Common Stock of warrant to the Holder.

Security: warrant
Shares: up to 13,823,512 shares of Common Stock
Purchaser: the Holder

Exact text from the filing

In consideration of the Holder’s immediate exercise of the Existing Warrants in accordance with the Inducement Agreement, the Company issued unregistered Series F Common Stock Purchase Warrants (the “New Warrants”) to purchase up to 13,823,512 shares of Common Stock (the “New Warrant Shares”).

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ADIAL PHARMACEUTICALS, INC. entered into Inducement Agreement with a certain holder named therein valued at approximately $2.86 million (effective 2025-11-25).

Action: entry
Agreement: equity purchase
Counterparty: a certain holder named therein
Value: approximately $2.86 million
Effective: 2025-11-25

Exact text from the filing

On November 25, 2025, Adial Pharmaceuticals, Inc. (the “Company”) entered into a warrant inducement agreement (the “Inducement Agreement”) with a certain holder named therein (the “Holder”) of Series C-1 Common Stock Purchase Warrants to purchase up to 4,025,000 shares of the Company’s common stock

View on SEC.gov

33 equity issuances filed in the last 30 days. Browse all equity issuances →

ADIAL PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-25-116666

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.